SCHEMBL7081087

SCHEMBL7081087

O=C(CC(=O)c1nccs1)c1cc(Cc2ccccc2)cc(Cn2cnccc2=O)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.40
ALDH1A1 P00352 3/20 0.40
PLA2G4A P47712 1/20 0.40
CES1 P23141 1/20 0.40
MAPK1 P28482 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
BRD4 O60885 1/20 0.34
BRD2 P25440 1/20 0.34
BRD3 Q15059 1/20 0.34
BRDT Q58F21 1/20 0.34
CYP1A2 P05177 2/20 0.33
CYP2D6 P10635 2/20 0.33
CYP2C9 P11712 2/20 0.33
CYP2C19 P33261 2/20 0.33
KDM4C Q9H3R0 1/20 0.33
HRH1 P35367 1/20 0.33
PLOD2 O00469 1/20 0.33
PLOD3 O60568 1/20 0.33
CYP3A4 P08684 1/20 0.33
HPGD P15428 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7079054 0.80 ALDH1A1 (0.40) SMN1; SMN2ALDH1A1BRD4BRD2BRD3
SCHEMBL7081335 0.78 ALDH1A1 (0.46) SMN1; SMN2ALDH1A1BRD4BRD2BRD3
SCHEMBL7085125 0.77 PLA2G4A (0.40) PLA2G4ACES1HRH1CACNA2D1F2
SCHEMBL7081226 0.76 PLA2G4A (0.39) PLA2G4ACES1HRH1CACNA2D1F2
SCHEMBL7078791 0.76 PLA2G4A (0.39) SMN1; SMN2ALDH1A1PLA2G4ACES1HRH1
SCHEMBL7078787 0.75 PLA2G4A (0.39) SMN1; SMN2PLA2G4ACES1HRH1CACNA2D1
SCHEMBL6479473 0.69 FEN1 (0.47) SMN1; SMN2ALDH1A1KDM4CCYP19A1
SCHEMBL27453621 0.69 KDM4C (0.55) SMN1; SMN2ALDH1A1CYP1A2CYP2D6KDM4C
SCHEMBL7078623 0.69 KLKB1 (0.38) BRD4BRD2BRD3BRDT
SCHEMBL7081880 0.67 CTNNB1 (0.41) SMN1; SMN2ALDH1A1BRD4BRD2BRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030229079-A1 1-(Aromatic- or heteroaromatic-substituted)-3-(heteroaromatic substituted)-1,3-propanediones and uses thereof PAYNE LINDA S (US) 2003-12-11 US claimed
US-20030229079-A1 1-(Aromatic- or heteroaromatic-substituted)-3-(heteroaromatic substituted)-1,3-propanediones and uses thereof PAYNE LINDA S (US) 2003-12-11 US disclosed
EP-1196384-A4 1-(AROMATIC- OR HETEROAROMATIC-SUBSTITUTED)-3-(HETEROAROMATIC SUBSTITUTED)-1,3-PROPANEDIONES AND USES THEREOF MERCK & CO INC (US) 2002-10-23 EP disclosed
EP-1196384-A1 1-(AROMATIC- OR HETEROAROMATIC-SUBSTITUTED)-3-(HETEROAROMATIC SUBSTITUTED)-1,3-PROPANEDIONES AND USES THEREOF Merck & Co., Inc. (US) 2002-04-17 EP disclosed
WO-2001000578-A1 1-(AROMATIC- OR HETEROAROMATIC-SUBSTITUTED)-3-(HETEROAROMATIC SUBSTITUTED)-1,3-PROPANEDIONES AND USES THEREOF MERCK & CO., INC. (US) 2001-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030229079-A1 1-(Aromatic- or heteroaromatic-substituted)-3-(heteroaromatic substituted)-1,3-propanediones and uses thereof CYP2S1, IMPDH1, IDO1 SMN1; SMN2 4337/4885ALDH1A1 145/4885PLA2G4A 3729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.